Surveyed oncologists who identified Sutent as having the best overall clinical profile assigned low satisfaction scores to the drugs out-of-pocket costs and its overall cost, said Decision Resources Analyst Ramya Kollipara, Ph.D. Although it is covered by many insurance companies, Sutent is not available generically and appears on the second tier of many MCO formularies."
"I think we're on the threshold of seeing a lot of things happen with our pipeline in the next 12 to 18 months," Germano said in an interview on the sidelines of the J.P. Morgan healthcare conference here.
Physicians, lawmakers and advocates continue to debate FDA's decision last month to revoke approval of Genentech's drug Avastin for breast cancer treatment, USA Today reports.
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma
Conclusion. Our study provides the first evidence that high VFA could be a predictive biomarker from shorter survival in patients given first-line antiangiogenic agents for mRCC.
Malignant effusion of chromophobe renal-cell carcinoma: Cytological and immunohistochemical findings
Malignant effusions because of renal-cell carcinoma (RCC) are an unusual event and occur in patients with papillary and clear cell tumors.
VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma
Von Teichman A et al. Multilocular cystic renal cell carcinoma is a rare renal cell carcinoma with an excellent prognosis.
A novel therapeutic approach combining a modified viral vector and a small molecular weight drug produced promising results in a mouse model of human kidney cancer.
In Career That Spans 50 Years, Professor Inspires Many to Pursue Professional Music Careers
Our TV studio is under construction and will be on the air in a few months.
Changes will enable researchers to take advantage of advances in molecular oncology.
|NeonCRM by Neon One|